Pilot Trial of Hydroxychloroquine as Add-On Therapy in Patients With Membranous Nephropathy
Introduction: Kidney Disease Improving Global Outcomes guidelines indicate that glucocorticoids and immunosuppressants comprise the first therapeutic regimens after 4 to 6 months of treatment for high-risk primary membranous nephropathy (PMN). However, some patients cannot achieve complete or partia...
Saved in:
| Main Authors: | Hongyu Yang, Guangping Sun, Xu Yang, Junjun Luan, Congcong Jiao, Qinglei Song, Feng Du, Beiru Zhang, Yanqiu Wang, Jeffrey B. Kopp, Hua Zhou |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Kidney International Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2468024924019442 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Application of hydroxychloroquine for IgA nephropathy
by: Xiao Yong-zhen, et al.
Published: (2021-01-01) -
Early reduction in total cholesterol to high-density lipoprotein cholesterol ratio predicts hydroxychloroquine efficacy in treating IgA nephropathy
by: Yaotong Shi, et al.
Published: (2024-12-01) -
Exploring the mechanism of proteinuria reduction by hydroxychloroquine in IgA nephropathy using network pharmacology and molecular mocking
by: Meiqi Lu, et al.
Published: (2025-07-01) -
Hydroxychloroquine sulfate for IgA nephropathy: mechanisms and therapeutic potential in improving proteinuria and alleviating disease progression - a literature review
by: Liao Yilei, et al.
Published: (2025-07-01) -
Clinical efficacy of tacrolimus combined with glucocorticoids for idiopathic membranous nephropathy
by: LING Yi-sheng, et al.
Published: (2016-01-01)